Core Insights - The article highlights Abbott's innovative iCGM technology, which represents a significant advancement in diabetes management, transitioning from mere monitoring to comprehensive management of blood glucose levels [1][2][4]. Product Innovation - Abbott showcased its new iCGM products, including the Libre Select and FreeStyle Libre 2 Plus sensors, at the China International Import Expo, emphasizing their compatibility with insulin pumps and clinical decision support [1][3]. - The iCGM technology is positioned as a non-auxiliary tool that directly informs diabetes treatment decisions, marking a critical evolution in the industry [2]. Clinical Impact - The introduction of iCGM is expected to enhance patient experience by providing continuous and trend-based data, shifting the perception of blood glucose monitoring from a burdensome task to a seamless part of daily life [4][5]. - iCGM also improves clinical efficiency for healthcare providers, allowing for easier access to continuous data and better communication with patients regarding treatment adjustments [5]. Market Strategy - Abbott is deepening its market presence in China through strategic partnerships, such as with WeDoctor, to create a comprehensive digital diabetes management system [6]. - The company aims to make advanced diabetes management technologies more accessible to patients, with a focus on localizing its iCGM digital connectivity capabilities [6]. Future Outlook - The article notes the challenges Abbott faces, including cost reduction, increasing insurance coverage, and educating healthcare providers and patients in grassroots markets [7]. - The significance of Abbott's high-standard technology and industry collaboration extends beyond commercial value, contributing to improved quality of life and aligning with China's "Healthy China 2030" strategic vision [7].

Core Insights - The eighth China International Import Expo (CIIE) is being held from November 5 to 10 in Shanghai, where Abbott showcases multiple new products from its FreeStyle family, including the only integrated continuous glucose monitoring system (iCGM) certified by international standards in the Chinese market [1] - Abbott aims to promote standardized development in the industry by releasing several expert consensus documents during the expo, focusing on key scenarios such as blood glucose management for cardiovascular patients and perioperative care [1][2] Group 1 - Abbott's FreeStyle Libre Select sensor and FreeStyle Libre 2 Plus sensor meet the strictest international accuracy standards for iCGM and are compatible with various digital devices, enhancing convenience for users [1] - The upcoming LibreView software is designed for diabetes patients and healthcare professionals, allowing real-time remote monitoring and automatic report generation [1] Group 2 - The "Expert Consensus on Blood Glucose Variability Management in Cardiovascular Disease Patients" is the first of its kind in China, aimed at encouraging cardiovascular doctors to actively manage blood glucose variability using intuitive indicators like Time in Range (TIR) [2] - The "Standard for the Construction of Perioperative CGM Centers" emphasizes the importance of continuous glucose monitoring (CGM) in managing blood glucose levels during surgery, which is crucial for preventing hidden hyperglycemia and hypoglycemia, ensuring surgical safety, and promoting postoperative recovery [2]